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Abstract
The synthesis of new multivalent architectures based on a trihydroxypiperidine α-fucosidase inhibitor is reported herein. Tetrava-
lent and nonavalent dendrimers were obtained by means of the click chemistry approach involving the copper azide-alkyne-
catalyzed cycloaddition (CuAAC) between suitable scaffolds bearing terminal alkyne moieties and an azido-functionalized piperi-
dine as the bioactive moiety. A preliminary biological investigation is also reported towards commercially available and human
glycosidases.
Introduction
Iminosugars are well-known naturally occurring glycomimetics
with a nitrogen atom replacing the endocyclic oxygen, mainly
recognized as inhibitors of carbohydrate-processing enzymes
(glycosidases) [1,2]. In quite sharp contrast the multivalent
effect, widely investigated in the field of carbohydrate–lectin
interactions [3], has remained essentially unexplored
concerning glycosidase inhibition up to 2010. Indeed, the first
examples of multivalent iminosugars gave disappointing results
in terms of inhibition and therefore were not encouraging [4-6].
However, following the first promising affinity enhancements
reported towards jack-bean α-mannosidase for a trivalent
derivative of 1-deoxynojirimycin [7], over the past six years the
multivalent effect in glycosidase inhibition has received an
increasing attention by the scientific community, rapidly
emerging as a hot topic in glycoscience. Three excellent recent
reviews collect the efforts of the researchers both in the syn-
thesis and in the biological evaluation of the new multivalent
structures [8-10]. In particular, remarkable high multivalent
effects towards jack-bean α-mannosidase were reported for
fullerene- [11], cyclodextrin- [12,13] and porphyrin- [14] based
scaffolds decorated with 1-deoxynojirimycin (DNJ) or 1-deoxy-
mannojirimycin as the bioactive iminosugars. Self-assembled
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Scheme 1: Double reductive amination on aldehyde 2 allowed the synthesis of trihydroxypiperidines, among which the enantiomer of natural com-
pound 1 and the N-alkylated piperidine 3.
DNJ-based glycopeptides also experienced a remarkable multi-
valent effect towards jack bean α-mannosidase [15].
Some mechanisms of action have been also proposed based on
the efforts recently devoted to understand the multivalent
glycosidase inhibition interactions [10]. Furthermore, some
applications of these multivalent systems have been reported
involving other glycosidases of therapeutic interest, in particu-
lar in the field of rare genetic diseases connected to misfolded
proteins [16-18].
While deoxynojrimycin (DNJ) is commonly employed to build
diversified multivalent architectures, relative few examples
have been reported with different bioactive molecules (namely
pyrrolidine- and pyrrolizidine-based iminosugars) [19-21].
Moreover, trivalent pyrrolidine derivatives have been recently
employed to probe the multivalent effect towards α-L-fucosi-
dase inhibition [22], which may be clinically relevant in the
treatment of fucosidosis metabolic disorder and Helicobacter
pylori infection, as well as in the elucidation of the biological
role of α-L-fucosidase in spermiogenesis and sperm maturation
[23].
Following our interest in the synthesis of natural alkaloids and
their unnatural analogs we recently developed a straightforward
synthetic strategy for the synthesis of diversely functionalized
trihydroxypiperidines through double reductive amination of the
D-mannose-derived aldehyde 2 (Scheme 1) [24,25].
Among the 1-azasugars accessed with this methodology, our
attention was drawn to the enantiomer of natural 3,4,5-tri-
hydroxypiperidine (1), ent-1, which showed good inhibitory
activity and excellent selectivity towards commercial bovine
kidney [25,26] and other mammalian [27] α-L-fucosidases.
Moreover, we recently found that N-alkylated trihydroxy-
piperidine 3 showed some chaperoning activity once incubated
with human fibroblasts derived from Gaucher bearing N370/
RecNcil mutations, being able to rescue the residual enzyme
activity up to 1.25 fold [28].
These findings, together with the opportunity to easily function-
alize the trihydroxypiperidine skeleton with an azido moiety at
the terminal N-alkyl chain, prompted us to investigate the multi-
merization of compound ent-1 with the aim of studying its
inhibitory activity when the molecule decorates a multivalent
scaffold. Herein we report the synthesis of a tetra- and a
nonavalent polyhydroxypiperidine iminosugar, by exploiting
the CuI-catalyzed azide-alkyne cycloadditions (CuAAC) [29-
32] with two different dendrimeric alkyne scaffolds.
Results and Discussion
The “masked” dialdehyde intermediate 2 was easily synthe-
sized in four steps and 80% overall yield from D-mannose
without the need of any chromatographic purification, by
following a slight modification of the published procedure
[24,33]. The versatility of our synthetic methodology allows
access to differently substituted N-alkylated trihydroxy-
piperidines by simply using the same aldehyde and different
amines as the nitrogen source in a double reductive amination
strategy [24,25].
In particular, catalytic hydrogenation with Pd(OH)2/C in MeOH
followed by reductive amination of the formed dialdehyde inter-
mediate with 3-azidopropyl-1-amine [34] in the presence of
NaBH3CN and AcOH allowed access to N-alkylated piperidine
4 in 67% yield (Scheme 2) [25].
With the key azido intermediate 4 in hands, we proceeded with
the synthesis of two different scaffolds bearing terminal alkyne
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Scheme 2: Synthesis of key azide intermediate 4 through the double
reductive amination strategy from “masked” dialdehyde intermediate 2.
moieties suitable for conjugation to compound 4. A preliminary
evaluation of the role of the valency in enhancing the inhibitory
activity of the iminosugar was investigated by synthesizing a
tetravalent and a nonavalent scaffold. The tetravalent scaffold 5
(Scheme 3) was obtained by propargylation of pentaerythritol
with propargyl bromide and NaH following a previously
published procedure [35], while the dendrimeric nonavalent
scaffold 6 (Scheme 3) was obtained in good yield from the reac-
tion of tris[(propargyloxy)methyl]aminomethane with tri-
mesoyl chloride, as we recently reported [21].
Scheme 3: Tetravalent and nonavalent alkyne scaffolds.
The CuAAC reaction of the azido derivative 4 (4.0 equivalents)
with scaffold 5 was performed with CuSO4/sodium ascorbate in
THF/H2O 2:1 in a MW reactor at 80 °C for 45 minutes,
affording the expected tetravalent iminosugar derivative 7 in
88% yield after flash column chromatography (Scheme 4).
Subsequent treatment of 7 in acidic MeOH at room temperature
for 18 hours gave the hydrochloride salt 8 (Scheme 4), which
was passed through ion exchange resin Dowex 50WX8-200
eluting successively with MeOH, H2O and 6% NH4OH. This
general purification procedure, successfully employed by us for
several deprotected monovalent compounds [25], resulted much
less efficient with the more basic and hydrophilic adduct 8.
Since in this case most of the compound was recovered in the
first fraction with MeOH as hydrochloride salt and only a small
amount in the NH4OH final fraction as free amine, we were
forced to turn to a protection/deprotection methodology. Hence,
the methanolic fraction was acetylated by treatment with excess
of pyridine and acetic anhydride, affording compound 9 with
91% yield after flash column chromatography. After treatment
with strongly basic resin Ambersep 900-OH, compound 8 was
obtained pure in 86% yield (Scheme 4). This compound and the
free amine previously recovered by DOWEX elution of 8.HCl
with 6% NH4OH were proved to be identical by 1H NMR
analysis.
To address the synthesis of the nonavalent compound avoiding
purification problems we first tried the deprotection of the
acetonide groups prior to CuAAC reaction. Compound 4 was
treated with 1 M HCl in MeOH at room temperature for
16 hours and then passed through Dowex 50WX8-200,
following the general purification procedure previously
described, to obtain the polyhydroxylated azido derivative 10
[25] in 90% yield. The CuAAC reaction of compound 10
(9 equiv) with the nonavalent alkyne scaffold 6, performed with
CuSO4/sodium ascorbate in THF/H2O 2:1 heating in a MW
reactor at 80 °C for 90 minutes, gave the nonavalent compound
11 in 23% yield, after flash column chromatography
(Scheme 5). The low yield observed for the click reaction of the
deprotected azido derivative 10 can be ascribed to the tricky
purification of 11 that was recovered from silica gel only by
eluting with 33% NH4OH due to its high basicity (see Experi-
mental section).
For this reason we decided to change the strategy by performing
the click reaction on the protected azido derivative 4, analo-
gously to what reported with the tetravalent scaffold 5. Reac-
tion of 4 (9 equiv) with the nonavalent alkyne scaffold 6 gave
compound 12 in excellent 92% yield (Scheme 5). After treat-
ment in acidic methanol at room temperature for 16 h, the
hydrochloride salt of the nonavalent adduct 11 was obtained in
quantitative yield. However, due to the purification problems
previously encountered for free amine 11, we decided to purify
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Scheme 4: Synthesis of the tetravalent adduct 7 by CuAAC reaction and its deprotection/purification process to obtain the final compound 8.
the nonavalent derivative 11·HCl by size exclusion chromatog-
raphy. Indeed, in this case, the use of the strongly basic resin
Ambersep 900-OH is hampered by the presence of the amidic
bonds in compound 11, which are not stable to strong basic
conditions. Therefore, 11·HCl was quickly passed over
Sephadex LH-20 resin, eluted with water, to obtain the purified
compound as hydrochloride salt, which was thus employed in
further biological evaluation.
In order to evaluate the relative inhibitory activity enhancement
of these new multimeric systems, a proper monovalent counter-
part was also synthesized. In particular, starting from
azidopiperidine 4, the CuAAC reaction was performed with
propargylamine (13) in the presence of CuSO4/sodium ascor-
bate in THF/H2O 2:1 at room temperature affording adduct 14
in 96% yield (Scheme 6). Final deprotection by treatment with
MeOH/HCl and eluting over ion exchange resin Dowex
50WX8-200, afforded the monovalent compound 15 in 77%
yield.
Searching for a multivalent effect towards α-fucosidase inhibi-
tion, the tetravalent compound 8, the nonavalent compound
11.HCl, as well as the monovalent 15, were assayed as glycosi-
dase inhibitors towards α-fucosidase (EC 3.2.1.51) from bovine
kidney. Eight further commercially available glycosidases were
also considered in order to investigate a possible change in
selectivity due to the polyhydroxypiperidine multimerization.
The results are summarized in Table 1, where inhibition of
simple 3,4,5-trihydroxypiperidine ent-1 is also reported for sake
of completeness.
Unfortunately, concerning the α-fucosidase inhibition, the
multimerization of active polyhydroxypiperidine ent-1 onto
both tetravalent and nonavalent scaffolds (8 and 11·HCl), as
well as the simple functionalization at the nitrogen atom (15)
led to a dramatic decrease of its inhibitory activity, demon-
strating a low tendency of this enzyme to be influenced by
multivalent presentation [22]. Conversely, some effect in the
change of selectivity can be observed as attested by the increase
on amyloglucosidase inhibition. In this case, while ent-1 does
not inhibit this enzyme at all, increasing inhibitory activity was
observed passing from its tetravalent derivative (57%) to the
nonavalent (86%) one. For this latter compound (11·HCl),
IC50 = 179 μM was calculated [36]. This outcome is particu-
larly desirable with multimeric iminosugars for increasing the
overall binding affinity of weak inhibitors, as recently pointed
out by Winum and Ulrich in a recent review [37]. It should also
be noted that analogous changes in selectivity towards different
Beilstein J. Org. Chem. 2015, 11, 2631–2640.
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Scheme 5: Synthesis of nonavalent adduct 11 by CuAAC reaction and its deprotection.
glycosidases comparing monovalent with multivalent poly-
meric iminosugars were recently documented [38].
However, by comparing the IC50 value of 11·HCl with the
monovalent counterpart 15 (relative inhibition potency = 6), an
effective multivalent effect cannot be claimed, since the
enhancement observed is not higher than 9-fold (the valency of
the dendrimeric compound).
Since in our experience the inhibition data towards commercial
and human glycosidases do not always match [28], we then
decided to evaluate the most promising nonavalent compound
11·HCl also towards human glycosidases. In particular, com-
pound 11·HCl was incubated at 1 mM in an extract from a pool
of leukocytes isolated from healthy donors and the α-fucosi-
dase activity was estimated by fluorescence measurements. A
46% inhibitory activity, calculated with respect to the blank
Beilstein J. Org. Chem. 2015, 11, 2631–2640.
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Table 1: Inhibitory activity of compounds ent-1, 8, 11.HCl, 15 towards glycosidases. Percentages of inhibition at 1mM of inhibitor (IC50 in parentheses
[µM]) were reported.
Commercially available glycosidases Evaluated compounds
ent-1 8 11·HCl 15
α-L-fucosidase
bovine kidney
89 [25]
(90.3)
45 41 28
α-galactosidase
coffee beans
– 39 58 –
β-galactosidase
Escherichia coli
Aspergillus oryzae
– – – –
α-glucosidase
Saccharomyces cerevisiae
rice
– 29 – –
amyloglucosidase
Aspergillus niger
– 57 86
(179)
45
(1100)
β-glucosidase
almonds
– – – –
α-mannosidase
jack beans
– – 32 –
β-mannosidase
snail
– – – –
β-N-acetylglucosaminidase
jack beans
– – – –
– : no inhibition was detected at 1 mM concentration of the corresponding compound.
Scheme 6: Synthesis of the monovalent iminosugar 15 by CuAAC
reaction and subsequent deprotection of the hydroxy groups.
control, was found: this data is in complete agreement with the
value obtained towards the commercial glycosidase. We finally
evaluated 11·HCl against two lysosomal enzymes, N-acetyl-
galactosamine-6-sulfate sulfatase (GALNS) and iduronate
2-sulfatase that, being dimers [39], are in principle more prone
to accept multivalent substrates. Actually only low inhibition
activities (50% and 69%, respectively) were measured for these
two enzymes, that represent appealing targets for the treatment
of rare metabolic disorders such as mucopolysaccharidosis type
IVA (Morquio A) and mucopolysaccharidosis type II (Hunter
syndrome).
Conclusion
In conclusion, the synthesis of two new dendrimeric
iminosugars (namely a tetravalent and a nonavalent) based on a
trihydroxypiperidine α-fucosidase inhibitor was achieved in this
work. Based on a key trihydroxypiperidine intermediate bearing
a terminal azido moiety, the CuAAC approach was investigated
either on the protected and deprotected iminosugar, with
different purification techniques employed in both cases. A
monomer reference compound was also synthesized for com-
parison. Biological evaluation against a panel of eleven
commercially available glycosidases showed that fucosidase
inhibition is lost, while an unexpected amyloglucosidase inhibi-
tion is observed with these dendrimeric compounds. Moreover,
preliminary evaluation towards human glycosidases showed
moderate inhibition towards particularly relevant enzymes, so
there is clearly space to consider expansion of our current
amyloglucosidase inhibitors so as to generate therapeutically
significant and specific inhibitors.
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Experimental
General methods: Commercial reagents were used as received.
All reactions were carried out under magnetic stirring and
monitored by TLC on 0.25 mm silica gel plates (Merck F254).
Column chromatographies were carried out on Silica Gel 60
(32–63 μm) or on silica gel (230–400 mesh, Merck). Yields
refer to spectroscopically and analytically pure compounds
unless otherwise stated. 1H NMR spectra were recorded on a
Varian Mercury-400 or on a Varian INOVA 400 instruments at
25 °C. 13C NMR spectra were recorded on a Varian Gemini-
200 or on a Varian Gemini-300 spectrometer. Chemical shifts
are reported relative to TMS (1H: δ = 0.00 ppm) and CDCl3
(13C: δ = 77.0 ppm). Integrals are in accordance with assign-
ments, coupling constants are given in Hz. For detailed peak
assignments 2D spectra were measured (COSY, HSQC,
NOESY, and NOE as necessary). Small scale microwave-
assisted syntheses were carried out in a microwave apparatus
for synthesis (CEM Discover) with an open reaction vessel and
external surface sensor. IR spectra were recorded with a BX
FTIR Perkin-Elmer system spectrophotometer. ESIMS spectra
were recorded with a Thermo Scientific™ LCQ fleet ion trap
mass spectrometer. Elemental analyses were performed with a
Perkin-Elmer 2400 analyzer. Optical rotation measurements
were performed on a JASCO DIP-370 polarimeter.
Protected tetravalent iminosugar 7: In a similar manner as
described in [21] to a solution of 4 (89 mg, 0.35 mmol) in
1.8 mL of a 2:1 THF/H2O mixture, CuSO4 (30 mol %, 3.8 mg,
0.024 mmol), sodium ascorbate (60 mol %, 9.5 mg,
0.048 mmol) and 5 (23 mg, 0.08 mmol) were added. The reac-
tion mixture was heated in a MW reactor at 80 °C for 45 min,
until TLC analysis showed the disappearance of the starting ma-
terial. After filtration through Celite®, the solvent was removed
under reduced pressure and the crude product was purified by
gradient FCC (from CH2Cl2/MeOH 10:1 to CH2Cl2/MeOH/
NH4OH 6% 10:1:0.1) affording pure 7 (92 mg, 0.07 mmol,
88%) as a pale yellow oil. Rf 0.32 (CH2Cl2/MeOH/NH4OH 6%
10:1:0.1); [α]D24 +4.88 (c 1.92, CHCl3); 1H NMR (400 MHz,
CDCl3) δ 7.67 (s, 4H, H-triazole), 4.54 (s, 8H, OCH2-triazole),
4.44 (t, J = 6.6 Hz, 8H, 3’-H), 4.32 (dd, J = 11.7, 5.3 Hz, 4H,
3-H), 4.05 (t, J = 4.7 Hz, 4H, 4-H), 3.98–3.95 (m, 4H, 5-H),
3.42 (s, 8H, CCH2O), 2.71 (dd, J = 12.0, 5.3 Hz, 4H, 2-Ha),
2.59 (dd, J = 11.7, 2.9 Hz, 4H, 6-Ha), 2.47–2.41 (m, 8H, 2-Hb +
6-Hb), 2.36 (t, J = 6.6 Hz, 8H, 1’-H), 2.11–2.03 (m, 8H, 2’-H),
1.49 (s, 12H, Me), 1.35 (s, 12H, Me) ppm; 13C NMR (50 MHz,
CDCl3) δ 145.1 (s, 4C, C-triazole), 123.3 (d, 4C, C-triazole),
109,0 (s, 4C, acetal), 77.3 (d, 4C, C-4), 72.2 (d, 4C, C-3), 68.9
(t, 4C, CCH2O), 68.0 (d, 4C, C-5), 64.8 (t, 4C, OCH2-triazole),
56.1 (t, 4C, C-6), 54.8 (t, 4C, C-2), 53.4 (t, 4C, C-1’), 47.7 (t,
4C, C-3’), 45.2 (s, CCH2O ), 28.3 (q, 4C, Me), 27.3 (t, 4C,
C-2’), 26.3 (q, 4C, Me) ppm; MS (ESI) m/z (%): 1335.83 (100)
[M + Na]+; IR (CDCl3): ν 3629, 3416, 3143, 2988, 2939, 2826,
2247, 1724, 1665, 1550, 1468, 1383, 1220, 1058 cm−1; anal.
calcd for C61H100N16O16: C, 55.78; H, 7.67; N, 17.06; found:
C, 55.74; H, 7.66; N, 16.83.
Peracetylated tetravalent iminosugars 9: In a similar manner
as described in [21] to a solution of 7 (85 mg, 0.065 mmol) in
35 mL of methanol, 0.22 mL (10.0 equiv) of 37% HCl were
added and the mixture was stirred at room temperature for
18 hours. After that a TLC analysis showed the disappearance
of the starting material, the solvent was removed under reduced
pressure. Successively elution with MeOH, H2O and 6%
NH4OH over ion exchange resin Dowex 50WX8-200 afforded
9 mg (0.008 mmol) of corresponding free amine and 42 mg
(0.032 mmol) of hydrochloride salt (MeOH fraction). This frac-
tion was dissolved in pyridine (1.2 mL) and acetic anhydride
(0.8 mL) was added. The solution was stirred at room tempera-
ture for 18 hours. Then, after concentration under reduced pres-
sure, the crude mixture was purified by gradient FCC (from
CH2Cl2/MeOH 20:1 to 5:1) affording pure 9 (48 mg,
0.029 mmol, 91%) as an oil. Rf 0.22 (CH2Cl2/MeOH 10:1);
[α]D22 −42.1 (c 1.45, CHCl3); 1H NMR (400 MHz, CDCl3) δ
7.55 (s, 4H, H-triazole), 5.22 (dt, J = 5.4, 2.7 Hz, 4H, 3-H),
5.07 (dt, J = 8.2, 4.4 Hz, 4H, 5-H), 4.90 (dd, J = 8.8, 3.4 Hz,
4H, 4-H), 4.48 (s, 8H, OCH2-triazole), 4.42–4.29 (m, 8H,
3’-H), 3.39 (s, 8H, CCH2O), 2.92 (d, J = 8.3 Hz, 4H, 6-Ha),
2.77 (dd, J = 12.1, 3.9 Hz, 4H, 2-Ha), 2.40–2.33 (m, 12H, 2-Hb
+ 1’-H), 2.21–2.15 (m, 4H, 6-Hb), 2.03 (s, 12H, Ac), 2.01–1.93
(m, 8H, 2’-H), 1.99 (s, 12H, Ac), 1.97 (s, 12H, Ac) ppm;
13C NMR (50 MHz, CDCl3) δ 169.2 (s, 12C, OAc), 144.3 (s,
4C, C-triazole), 122.3 (d, 4C, C-triazole), 70.6 (d, 4C, C-4),
68.9 (t, 4C, CCH2O), 67.8 (d, 4C, C-5), 67.5 (d, 4C, C-3), 64.7
(t, 4C, OCH2-triazole), 53.6 (t, 4C, C-2), 53.2 (t, 4C, C-6), 53.0
(t, 4C, C-1’), 47.4 (t, 4C, C-3’), 45.3 (s, CCH2O ), 27.2 (t, 4C,
C-2’), 20.8-20.5 (q, 12C, OAc) ppm; MS (ESI) m/z (%):
1679.92 (100) [M + Na]+; IR (CDCl3): ν 3451, 3145, 2960,
2874, 2825, 2258, 2246, 1743, 1663, 1470, 1437, 1372, 1231,
1049 cm−1; anal. calcd for C73H108N16O28: C, 52.89; H, 6.57;
N, 13.52; found: C, 52.52; H, 6.25; N, 13.90.
Polyhydroxylated tetravalent iminosugar 8: In a similar
manner as described in [21] a suspension of 9 (31 mg,
0.019 mmol) and ion exchange resin Ambersep-900 OH
(500 mg) in 10 mL of methanol was slowly stirred at room
temperature for 16 h. After filtration of resin on Celite®, the
solvent was removed under reduced pressure affording pure 8
(19 mg, 0.016 mmol, 86% yield) as a waxy solid. [α]D23 −13.0
(c 1.1, H2O); 1H NMR (400 MHz, D2O) δ 7.83 (s, 4H, H-tria-
zole), 4.38 (s, 8H, OCH2-triazole), 4.31 (t, J = 6.8 Hz, 8H,
3’-H), 3.86–3.82 (m, 4H, 3-H), 3.72 (td, J = 8.8, 4.4 Hz, 4H,
5-H), 3.58–3.34 (m, 4H, 4-H), 3.25 (s, 8H, CCH2O), 2.72–2.65
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(m, 8H, 2-Ha + 6-Ha), 2.28–2.11 (m, 12H, 2-Hb + 1’-H),
2.00–1.9 (m, 12H, 6-Hb + 2’-H) ppm; 13C NMR (50 MHz,
D2O) δ 143.2 (s, 4C, C-triazole), 124.0 (d, 4C, C-triazole), 72.8
(d, 4C, C-4), 67.1 (t, 4C, CCH2O), 66.8 (d, 4C, C-3), 66.6 (d,
4C, C-5), 62.6 (t, 4C, OCH2-triazole), 55.7 (t, 4C, C-6), 54.8 (t,
4C, C-2), 52.9 (t, 4C, C-1’), 47.7 (t, 4C, C-3’), 43.7 (s,
CCH2O), 25.4 (t, 4C, C-2’) ppm; MS (ESI) m/z (%): 1175.79
(100) [M + Na]+; anal. calcd for C49H84N16O16: C 51.03, H
7.34, N 19.43; found: C, 50.71; H, 7.46; N, 19.62.
Deprotected nonavalent iminosugar 11: Analogously as
described in [21] to a solution of 10 (50 mg, 0.23 mmol) in
3 mL of a 2:1 THF/H2O mixture, CuSO4 (30 mol %, 1.2 mg,
0.007 mmol), sodium ascorbate (80 mol %, 4.1 mg,
0.021 mmol) and 6 (21 mg, 0.025 mmol) were added. The reac-
tion mixture was heated in a MW reactor at 80 °C for 90 min,
until TLC analysis showed the disappearance of the nonavalent
alkyne scaffold. After filtration through Celite®, the solvent was
removed under reduced pressure and the crude product was
purified by gradient FCC (from CH2Cl2/MeOH/NH4OH 6%
1:1:0.3 to NH4OH 33%) to afford pure 11 (16 mg, 0.006 mmol,
23%) as a pale yellow oil. Rf 0.19 (CH2Cl2/MeOH/NH4OH
33% 1:1:0.3); [α]D21 −21.31 (c 1.30, H2O); 1H NMR
(400 MHz, D2O) δ 7.87 (s, 3H, Ar), 7.82 (s, 9H, H-triazole),
4.45 (s, 18H, OCH2-triazole), 4.22 (t, J = 6.7 Hz, 18H, 3’-H),
3.82–3.80 (m, 9H, 3-H), 3.71–3.66 (m, 27H, 5-H +
OCH2CNH), 3.33–3.29 (m, 9H, 4-H), 2.72 (d, J = 9.9 Hz, 9H,
6-Ha), 2.66 (d, J = 10.3 Hz, 9H, 2-Ha), 2.28–2.23 (m, 18H,
1’-H), 2.17 (d, J = 10.2 Hz, 9H, 6-Hb), 1.96–1.84 (m, 27H,
2-Hb + 2’-H) ppm; 13C NMR (100 MHz, D2O) δ 168.1 (s, 3C,
C=O), 143.9 (s, 9C, C-triazole), 135.1 (s, 3C, Ar), 129.0 (d, 3C,
Ar), 124.9 (d, 9C, C-triazole), 73.2 (d, 9C, C-4), 67.2 (d, 9C,
C-3), 67.1 (d + t, 18C, C-5 + OCH2CNH), 63.5 (t, 9C, OCH2-
triazole), 60.7 (s, 3C, OCH2CNH), 56.0 (t, 9C, C-2), 55.3 (t,
9C, C-6), 53.6 (t, 9C, C-1’), 48.2 (t, 9C, C-3’), 25.9 (t, 9C,
C-2’) ppm; MS (ESI) m/z (%): 958.92 (100) [M/3 + Na]+; anal.
calcd for C120H195N39O39: C, 51.33; H, 7.00; N, 19.45; found:
C, 51.54; H, 6.79; N, 19.69.
Protected nonavalent iminosugar 12: In a similar manner as
described in [21] to a solution of 4 (57 mg, 0.22 mmol) in 3 mL
of a 2:1 THF/H2O mixture, CuSO4 (30 mol %, 1.2 mg,
0.007 mmol), sodium ascorbate (60 mol %, 2.9 mg,
0.014 mmol) and 6 (20 mg, 0.024 mmol) were added. The reac-
tion mixture was heated in a MW reactor at 80 °C for 45 min,
until TLC analysis showed the disappearance of the starting ma-
terial. After filtration through Celite®, the solvent was removed
under reduced pressure and the crude product was purified by
gradient FCC (from CH2Cl2/MeOH 10:1 to CH2Cl2/MeOH 1:1)
and then by size exclusion chromatography, employing
Sephadex LH-20® resin and eluting with MeOH, to afford pure
12 (67 mg, 0.021 mmol, 92%) as a pale yellow oil. Rf 0.29
(CH2Cl2/MeOH 1:1); [α]D29 +4.18 (c 0.70, CHCl3); 1H NMR
(400 MHz, CDCl3) δ 8.14 (s, 3H, Ar), 7.72 (s, 9H, H-triazole),
7.11 (s, 3H, NH), 4.56 (s, 18H, OCH2-triazole), 4.38 (t, J = 6.4
Hz, 18H, 3’-H), 4.24 (q, J = 5.4 Hz, 9H, 3-H), 3.96 (t, J = 4.9
Hz, 9H, 4-H), 3.89−3.85 (m, 27H, 5-H + OCH2CNH),
2.60–2.43 (m, 27H, 2-H + 1’-Ha), 2.82–2.51 (m, 27H, 6-H +
1’-Hb), 1.99–1.95 (m, 18H, 2’-H), 1.43 (s, 27H, Me), 1.35 (s,
27H, Me) ppm; 13C NMR (100 MHz, CDCl3) δ 166.5 (s, 3C,
C=O), 144.4 (s, 9C, C-triazole), 135.6 (s, 3C, Ar), 128.6 (d, 3C,
Ar), 123.7 (d, 9C, C-triazole), 109,0 (s, 9C, acetal), 77.5 (d, 9C,
C-4), 72.3 (d, 9C, C-3), 68.4 (t, 9C, OCH2CNH), 68.1 (d, 9C,
C-5), 64.7 (t, 9C, OCH2-triazole), 60.6 (s, 3C, OCH2CNH),
56.1 (t, 9C, C-1’), 54.7 (t, 9C, C-2), 53.4 (t, 9C, C-6), 47.8 (t,
9C, C-3’), 28.3 (q, 9C, Me), 27.2 (t, 9C, C-2’), 26.4 (q, 9C, Me)
ppm; MS (ESI) m/z (%): 1078.53 (100) [M/3 + Na]+; IR
(CDCl3): ν 3346, 2989, 2941, 2823, 1663, 1517, 1467, 1382,
1242, 1090, 1057 cm−1; anal. calcd for C147H231N39O39:
C, 55.72; H, 7.35; N, 17.24; found: C, 55.44; H, 7.69; N, 16.99.
Hydrochloride salt of polyhydroxylated nonavalent
iminosugars 11.HCl: To a solution of 12 (60 mg, 0.019 mmol)
in 7 mL of methanol, 0.20 mL of HCl 1 M were added and the
mixture was stirred at room temperature for 16 hours, until a
TLC analysis attested the disappearance of the starting material.
The solvent was removed under reduced pressure and the crude
product was purified by size exclusion chromatography,
employing Sephadex LH-20® resin and eluting with H2O, to
afford pure hydrochloride salt of 11 (55 mg, 0.019 mmol,
100%) as a waxy solid; [α]D29 = −13.50 (c 2.30, H2O);
1H NMR (400 MHz, D2O) δ 7.91 (s, 3H, Ar), 7.90 (s, 9H,
H-triazole), 4.49 (s, 18H, OCH2-triazole), 4.36 (t, J = 6.6 Hz,
18H, 3’-H), 4.08–4.05 (m, 9H, 3-H), 3.94 (td, J = 7.6, 3.7 Hz,
9H, 4-H), 3.79 (s, 18H, OCH2CNH), 3.61 (br s, 9H, 5-H),
3.25–3.21 (m, 9H), 3.14 (br s, 9H), 3.03–3.00 (m, 27H), 2.81
(br s, 9H), 2.26–2.17 (m, 18H, 2’-H) ppm; 13C NMR
(100 MHz, D2O) δ 168.5 (s, 3C, C=O), 144.0 (s, 9C,
C-triazole), 135.2 (s, 3C, Ar), 129.0 (d, 3C, Ar), 125.3 (d, 9C,
C-triazole), 70.4 (d, 9C, C-4), 67.3 (d, 9C, OCH2CNH), 65.4 (d,
9C, C-3), 64.9 (t, 9C, C-5), 63.4 (t, 9C, OCH2-triazole), 60.7 (s,
3C, OCH2CNH), 53.7 (t, 27C, C-1’ + C-2 + C-6), 47.3 (t, 9C,
C-3’), 24.4 (t, 9C, C-2’) ppm; MS (ESI) m/z (%): 936.57 (100)
[M/3 + H]+.
Protected monovalent iminosugar 14: Analogously as
described in [21] to a solution of 4 (49 mg, 0.190 mmol) in
3 mL of a 2:1 THF/H2O mixture, CuSO4 (30 mol %, 9.1 mg,
0.057 mmol), sodium ascorbate (60 mol %, 23 mg,
0.114 mmol) and 13 (12 mg, 0.220 mmol) were added. The
reaction mixture was stirred at room temperature for 16 h, until
TLC analysis showed the disappearance of the starting material.
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After filtration through Celite®, the solvent was removed under
reduced pressure and the crude product was purified by gradient
FCC (from CH2Cl2/MeOH 20:1 to CH2Cl2/MeOH/NH4OH 6%
10:1:0.2) affording pure 14 (57 mg, 0.183 mmol, 96%) as a pale
yellow oil. Rf 0.88 (CH2Cl2/MeOH/NH4OH 6% 10:1:0.2);
[α]D28 −13.36 (c 1.25, MeOH); 1H NMR (400 MHz, CD3OD) δ
7.91 (s, 1H, H-triazole), 4.48–4.42 (m, 2H, 3’-H), 4.28 (dd, J =
8.8, 3.9 Hz, 1H, 3-H), 3.93 (s, 2H, CH2NH2), 3.86–3.78 (m, 2H,
4-H + 5-H), 2.87 (dd, J = 12.2, 3.1 Hz, 1H, 2-Ha), 2.70–2.64
(m, 1H, 6-Ha), 2.51–2.43 (m, 1H, 2-Hb), 2.40–2.30 (m, 2H,
1’-H), 2.11–2.03 (m, 3H, 6-Hb + 2’-H), 1.48 (s, 3H, Me), 1.33
(s, 3H, Me) ppm; 13C NMR (100 MHz, CD3OD) δ 146.8 (s,
C-triazole), 122.6 (d, C-triazole), 108.7 (s, acetal), 78.7 (d,
C-4), 73.1 (d, C-3), 69.0 (d, C-5), 56.0 (t, C-6), 53.7 (t, C-2),
53.5 (t, C-1’), 47.7 (t, C-3’), 35.8 (t, CH2NH2), 27.2 (q, Me),
26.9 (t, C-2’), 25.2 (q, Me) ppm; MS (ESI) m/z (%): 312.17
(100) [M + H]+; IR (MeOH): ν 3419, 3305, 3146, 2994, 2808,
1469, 1422, 1381, 1106, 1062 cm−1; anal. calcd for
C14H25N5O3: C, 54.00; H, 8.09; N, 22.49; found: C, 55.88; H,
8.15; N, 22.81.
Deprotected monovalent iminosugar 15: In a similar manner
as described in [25] a solution of 14 (24 mg, 0.077 mmol) in
MeOH (3 mL) was left stirring with 1 M HCl (7 drops) at room
temperature for 16 h. The crude mixture was concentrated to
yield the hydrochloride salt of 15. The corresponding free
amine was obtained by passing the hydrochloride salt through
DOWEX 50XW8-100 ion-exchange resin. Elution with 6%
NH4OH afforded the free base 15 (16 mg, 0.059 mmol, 77%).
[α]D24 −11.43 (c 0.70, MeOH); 1H NMR (400 MHz, CD3OD) δ
7.91 (s, 1H, H-triazole), 4.42–4.34 (m, 2H, 3’-H), 3.97 (s, 2H,
CH2NH2), 3.80 (dt, J = 5.7, 2.9 Hz, 1H, 3-H), 3.68 (td,
J = 7.9, 4.1 Hz, 1H, 4-H), 3.30 (d, J = 4.4 Hz, 1H, 5-H),
2.70−2.59 (m, 2H, 2-Ha + 6-Ha), 2.31–2.17 (m, 3H, 2-Hb +
1’-H), 2.03–1.93 (m, 3H, 6-Hb + 2’-H) ppm; 13C NMR (50
MHz, CD3OD) δ 144.1 (s, C-triazole), 123.3 (d, C-triazole),
73.9 (d, C-4), 68.3 (d, C-5), 67.9 (d, C-3), 56.5 (t, C-6), 56.1 (t,
C-2), 53.7 (t, C-1’), 47.9 (t, C-3’), 35.2 (t, CH2NH2), 26.9 (t,
C-2’) ppm; MS (ESI) m/z (%): 293.87 (100) [M + Na]+; anal.
calcd for C11H21N5O3: C, 48.70; H, 7.80; N, 25.81; found: C,
48.49; H, 7.71; N, 26.19.
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